Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

Related Citations for PubMed (Select 22497699)

1.

HIV drug resistance interpreted by cumulative versus last genotypes in HIV-infected patients with multiple treatment failures.

Punyacam P, Iemwimangsa N, Chantratita W, Sukasem C, Sungkanuparph S.

Curr HIV Res. 2012 Apr;10(3):271-4.

PMID:
22497699
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
4.

Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication.

Delaugerre C, Braun J, Charreau I, Delarue S, Nere ML, de Castro N, May T, Marchou B, Simon F, Molina JM, Aboulker JP; ANRS 138-EASIER study group.

HIV Med. 2012 Oct;13(9):517-25. doi: 10.1111/j.1468-1293.2012.01002.x. Epub 2012 Mar 14.

PMID:
22416781
5.

Prevalence of HIV drug resistance mutation in the northern Indian population after failure of the first line antiretroviral therapy.

Sinha S, Shekhar RC, Ahmad H, Kumar N, Samantaray JC, Sreenivas V, Khan NH, Mitsuyasu RT.

Curr HIV Res. 2012 Sep;10(6):532-8.

PMID:
22716105
6.

Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.

Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, Hoepelman AI, Schuurman R, Wensing AM.

Antivir Ther. 2012;17(2):377-86. doi: 10.3851/IMP2010. Epub 2011 Dec 2.

PMID:
22297391
7.

Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.

Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):23-31. doi: 10.1097/QAI.0b013e318227fc34.

PMID:
21694603
8.

HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S.

Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):83-8.

PMID:
19323038
9.

Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.

Zolfo M, Schapiro JM, Phan V, Koole O, Thai S, Vekemans M, Fransen K, Lynen L.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):727-35. doi: 10.1089/AID.2010.0037. Epub 2010 Nov 23.

PMID:
20854169
10.

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.

Ghosn J, Wirden M, Ktorza N, Peytavin G, Aït-Mohand H, Schneider L, Dominguez S, Bricaire F, Calvez V, Costagliola D, Katlama C.

AIDS. 2005 Oct 14;19(15):1643-7.

PMID:
16184034
11.

Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.

Ortu M, Vitiello P, Adorni F, Rossotti R, Di Vincenzo P, Vigano O, Galli M, Rusconi S.

Curr HIV Res. 2011 Dec 1;9(8):625-9.

PMID:
22211659
12.

Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.

Badri SM, Adeyemi OM, Max BE, Hota BN, Barker DE.

AIDS Patient Care STDS. 2007 Aug;21(8):544-50.

PMID:
17711379
13.

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P.

Lancet. 1999 Jun 26;353(9171):2195-9. Erratum in: Lancet 1999 Sep 25;354(9184):1128.

PMID:
10392984
14.

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.

Clin Infect Dis. 2007 Feb 1;44(3):447-52. Epub 2006 Dec 27.

15.

Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.

Vidal C, Arnedo M, Garcia F, Mestre G, Plana M, Cruceta A, Capon A, Gallart T, Miro JM, Pumarola T, Gatell JM.

Antivir Ther. 2002 Dec;7(4):283-7.

PMID:
12553483
16.

HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.

Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B.

Int J STD AIDS. 2007 Dec;18(12):832-4.

PMID:
18073016
17.

Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: an observational cohort study in rural China.

Zhao Y, Mu W, Harwell J, Zhou H, Sun X, Cheng Y, Li C, Zhang F.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):47-53. doi: 10.1097/QAI.0b013e318229f2a2.

PMID:
21725248
18.

Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.

Svedhem V, Lindkvist A, Lidman K, Sönnerborg A.

J Med Virol. 2002 Dec;68(4):473-8.

PMID:
12376953
19.

Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.

Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2003 Oct;8(5):443-54.

PMID:
14640392
20.

[Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].

Oette M, Kaiser R, Däumer M, Fätkenheuer G, Rockstroh JK, Knechten H, Mitrenga D, Beerenwinkel N, Sagir A, Pfister H, Häussinger D.

Dtsch Med Wochenschr. 2007 May 4;132(18):977-82. German.

PMID:
17457780
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk